Cerebral cavernous malformation
Conditions
Interventions
A group:phase I: rapamycin capsule 1mg/m2 qd po
phase II: blank control
B group:phase I: blank control
phase II: rapamycin capsule 1mg/m2 qd po
Sponsors
The first hospital of Yichang
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects aged over 18 years; 2. Patients with cerebral cavernous angiomatosis confirmed by nerve biopsy or MRI; 3. Subjects with Karnofsky performance status of 70 or above. 4. Volunteers who have signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with acute and chronic infection; 2. Patients with liver, kidney and bone marrow dysfunction; 3. Neutrophils < 1.0 x 10^9 / L; 4. Subjects allergic to rapamycin; 5. Pregnant and lactating women; 6. Liver transplantation and lung transplantation; 7. Patients with severe hyperlipidemia; 8. Subjects who abuse alcohol, drugs or drugs (for example, laxatives); 9. Patients who participate in another clinical trial that may affect the purpose of this study at the same time or within one month; 10. Subjects who had used rapamycin in the past one month; 11. Subjects with a history of major surgery in the past 12 weeks; 12. Subjects with a history of live vaccination 4 weeks ago; 13. Subjects with secondary cerebral hemorrhage; 14. Subjects considered unsuitable for clinical trials for other reasons by researchers; 15. The subjects were willing to treat cerebral cavernous hemangioma by surgery or radiotherapy within one year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volume changes in cerebral cavernous malformation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood concentration of rapamycin;Quality of life scale score; | — |
Countries
China
Contacts
Public ContactJun Wei
The First Hospital of Yichang
Outcome results
None listed